Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NRL 1049

Next Previous
Drug Profile

NRL 1049

Alternative Names: BA 1049; NRL-1049

Latest Information Update: 29 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAxone Biosciences
  • Developer BioAxone Biosciences; Neurelis
  • Class Amines; Antineoplastics; Eye disorder therapies; Isoquinolines; Piperidines; Small molecules; Sulfones; Vascular disorder therapies
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cavernous haemangioma
  • No development reported Spinal cord injuries
  • Discontinued Cancer; Eye disorders

Most Recent Events

  • 24 Mar 2023 Phase-I clinical trials in Cavernous haemangioma (In volunteers) in USA (PO)
  • 24 Mar 2023 Pharmacodynamics data from a preclinical trial in Cavernous haemangioma released by Neurelis
  • 23 Mar 2023 The US FDA approves IND application for NRL 1049 for Cavernous haemangioma in the US, prior to March 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top